Exhibit 99.4
Terms and conditions of the BSA2018
ERYTECH PHARMA
Public limited company (société anonyme) with share capital of €1,794,003.50
Headquarters: 60, avenue Rockefeller, 69008 Lyon
Lyon Trade Register 479 560 013
TERMS AND CONDITIONS
DETACHABLE ORDINARY STOCK
SUBSCRIPTION WARRANTS REFERRED TO AS BSA2018
Adopted by the Board of Directors on March 8, 2019
Based on the authorization granted under the Forty-Third Resolution of the Combined Shareholders’ Meeting of Erytech Pharma, a limited liability company (société anonyme) with share capital of €1,794,003.50 and headquarters at 60, avenue Rockefeller, 69008 Lyon, registered with the Lyon Trade and Companies under number 479 560 013 (the “Company”) on June 28, 2018, the Board of Directors decided at its March 8, 2019 meeting to adopt the terms and conditions (the “Terms and Conditions”) of the issuance of detachable ordinary stock subscription warrants (the “BSA2018”) under the stipulations of ArticlesL. 228-91et seq. of the Commercial Code.
Except where otherwise decided by the Board of Directors, the Terms and Conditions shall be applicable to all BSA2018 issuances that may be approved by the Board of Directors on the basis of the forty-third resolution adopted by the Company’s Combined Shareholders’ Meeting of June 28, 2018, within eighteen (18) months following that Shareholders’ Meeting.
| | |
“BSA2018” | | means the detachable stock subscription warrants issued by the Company’s Board of Directors within eighteen (18) following the forty-third resolution adopted by the Company’s Combined Shareholders’ Meeting of June 28, 2018. |
| |
“Disability” | | means a disability of the BSA2018 warrant holder corresponding to the second or third category stipulated in ArticleL.341-4 of the Social Security Code. |
| |
“Terms and Conditions” | | means these Terms and Conditions of the BSA2018 as adopted by the Company’s Board of Directors on March 8, 2019. |
| |
“Company” | | means Erytech Pharma, a French Joint Stock Company. |
Pursuant to the Thirtieth Resolution of the Company’s Combined Shareholders’ Meeting of June 28, 2018, the Board of Directors was authorized to issue and grant detachable stock subscription warrants entitling their holders to subscribe maximum 50,000 ordinary shares of the Company, adjusted to account, as applicable, of any stock split or reverse split; note that the total amount of capital increases that could be carried out in application of the BSA2018 and of the bonus shares plans and stock subscription options adopted by the Board of Directors on June 28, 2018, may not exceed the 325,000 ordinary shares ceiling.